Table 2.
Summary of findings from various mouse lines in developmental and neonatal mice
| Cre/CreER line | Developmental time point induced |
Time analyzed |
Reference | TAM dose | Reporter | Recombination efficiency |
Observations |
|---|---|---|---|---|---|---|---|
| Cx3cr1YFP–CreER(Litt) | P3–P5 | P7–P9 | Sahasrabuddhe and Ghosh14 | 50 μg (IG) | none | not reported | artifactual production of reactive microglia in a CreER- and TAM-dependent fashion |
| Cx3cr1CrerER (Jung) | P1, P2, P3 | P7, P30, P120 | Arnold et al.30 | 1 mg/mL (50 μL) (IG) | Ai14: tdTomato | 95% | lower penetrance of Tgfbr2 recombination; microglia and BAMs are specifically recombined; no artifactual reactive microglia observed |
| Tmem119CreER | P2, P3, P4 | P14 | Kaiser et al.10 | 20 mg/mL (5 μL) (IG) | Ai14: tdTomato | cortex, 90%–100%; caudate putamen, 96%–100%; hippocampus, 94%–100% | endothelial recombination in addition to macrophages; potential mural cell recombination |
| P2ry12CreER | Embryonic day 13.5 (E13.5)–E17.5 | E18.5 | McKinsey et al.8 | 20 mg/mL (150 μL) oral gavage | Ai14: tdTomato | not reported | widespread recombination of microglia; low pial macrophage recombination (8%–12%); potential recombination in microglial precursors |